echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 300 million US dollars to join hands again!

    300 million US dollars to join hands again!

    • Last Update: 2022-06-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 12, 2022, Takeda and Engitix entered into an agreement to expand an existing collaboration to the discovery and development of fibro-stenotic inflammatory bowel disease (IBD), including new treatments for Crohn's disease and ulcerative colitis


    Takeda is the first and only Asian company to be ranked among the top 10 global pharmaceutical companies


    Engitix's R&D pipeline

    The ECM platform is applicable to multiple organs, indications and fields


    Fibrotic strictures are fibrotic obstructions caused by intestinal inflammation, most commonly seen in Crohn's disease (CD) in IBD


    According to the report of GrandViewer Search, the overall market size of IBD was 15.


    CD can involve the entire gastrointestinal tract and is a discontinuous full-thickness inflammation, most often involving the terminal ileum, colon, and perianal region


    In the face of such a huge digestion market, whether Takeda can open up a new situation for future development by expanding cooperation, let us stay tuned!

    Original in English: https://engitix.


    https://engitix.
    com/engitix-announces-expanded-collaboration-and-licensing-agreement-with-takeda-to-develop-new-anti-fibrotic-therapies-in-inflammatory-bowel-disease/
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.